| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 89,945 | 93,199 |
| Depreciation and amortization | 21,357 | 14,942 |
| Amortization of debt discount | 925 | 631 |
| Non-cash operating lease expense | 5,304 | 4,037 |
| Unrealized gain on investments in equity securities | 1,663 | 613 |
| Realized loss on available-for-sale investments | -2,283 | -1,888 |
| Gain on divested business | 120,047 | 116,662 |
| Stock-based compensation expense | 8,601 | 6,075 |
| Loss on disposal of property and equipment | -149 | -105 |
| Change in credit losses | 157 | 48 |
| Excess and obsolete inventory | 110 | -36 |
| Change in contingent consideration | -5,207 | -5,206 |
| Accounts receivable | 7,828 | 5,945 |
| Inventories | 2,088 | 1,667 |
| Prepaid expenses and other current assets | -4,521 | -3,188 |
| Deposits | 185 | 170 |
| Operating lease liabilities | -3,967 | -2,935 |
| Accounts payable and other accrued expenses | -2,723 | -2,594 |
| Accrued compensation and related expenses | -209 | -1,568 |
| Deferred revenue | 288 | 519 |
| Net deferred tax liability | 778 | 1,077 |
| Net cash used in operating activities | -9,499 | -11,687 |
| Purchases of property and equipment | 10,972 | 7,519 |
| Software development costs | 2,649 | 2,062 |
| Proceeds from divested business | 210,239 | 210,239 |
| Sales/maturities of short-term investments | 54,589 | 36,001 |
| Patent and trademark costs | 940 | 698 |
| Net cash provided by investing activities | 250,267 | 235,961 |
| Proceeds from exercise of stock options | 3,973 | 2,950 |
| Repayment of convertible senior notes-Senior Notes2026 | - | 0 |
| Repurchase of common stock | 8,004 | 4,259 |
| Repayment of convertible senior notes-Senior Notes2025 | 14,344 | 14,344 |
| Repayment of notes payable | -121 | -80 |
| Repayment of finance lease liabilities | 425 | 320 |
| Net cash used in financing activities | -18,921 | -16,053 |
| Effect of exchange rates on cash and cash equivalents | -11,325 | -10,094 |
| Net change in cash and cash equivalents | 210,522 | 198,127 |
| Cash and cash equivalents at beginning of period | 45,289 | - |
| Cash and cash equivalents at end of period | 255,811 | - |
Cryoport, Inc. (CYRX)
Cryoport, Inc. (CYRX)